Market research
SBTX.LSE SkinBioTherapeutics Plc
LSE GBP Healthcare
Latest close
As of 30 Apr 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 29
- Dividend yield
- Not available
- Beta
- 0.2
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BF33H870
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 29
- Dividend yield
- Not available
- Beta
- 0.2
About
About SkinBioTherapeutics Plc
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Research context
SkinBioTherapeutics Plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SBTX.LSE discussion.
5 years, 6 months ago
SkinBioTherapeutics Plc is currently in a long term uptrend where the price is trading 48.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-412K since the same quarter in the previous year.
Finally, its free cash flow fell by 9.3% to $-333K since the same quarter in the previous year.
Based on the above factors, SkinBioTherapeutics Plc gets an overall score of 2/5.